Eagle Pharmaceuticals (EGRX) Short Interest Ratio & Short Volume $2.10 +0.13 (+6.33%) As of 06/4/2025 03:54 PM Eastern Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Eagle Pharmaceuticals Short Interest DataEagle Pharmaceuticals (EGRX) has a short interest of 54,400 shares. This marks a -14.73% decrease in short interest from the previous month. The short interest ratio (days to cover) is 24.7, indicating that it would take 24.7 days of the average trading volume of 10,327 shares to cover all short positions.Current Short Interest54,400 sharesPrevious Short Interest63,800 sharesChange Vs. Previous Month-14.73%Dollar Volume Sold Short$105,536.00Short Interest Ratio24.7 Days to CoverLast Record DateMay 15, 2025Outstanding Shares12,987,000 sharesPercentage of Shares Shorted0.42%Today's Trading Volume32,628 sharesAverage Trading Volume10,327 sharesToday's Volume Vs. Average316% Short Selling Eagle Pharmaceuticals? Sign up to receive the latest short interest report for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartEGRX Short Interest Over TimeEGRX Days to Cover Over TimeEGRX Percentage of Float Shorted Over Time Eagle Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202554,400 shares $105,536.00 -14.7%N/A24.7 $1.94 4/30/202563,800 shares $125,048.00 -43.4%N/A2.3 $1.96 4/15/2025112,800 shares $203,040.00 -0.1%N/A3.7 $1.80 3/14/2025112,500 shares $146,250.00 No ChangeN/A13.4 $1.30 2/28/2025112,500 shares $135,000.00 -8.8%N/A5.4 $1.20 2/14/2025123,400 shares $144,378.00 -63.5%N/A8.2 $1.17 1/31/2025337,700 shares $270,160.00 -6.5%N/A13.8 $0.80 1/15/2025361,000 shares $223,820.00 +0.3%N/A34.7 $0.62 9/30/2024371,600 shares $1.39 million +6.0%2.9%1.7 $3.73 9/15/2024350,500 shares $1.51 million -17.3%3.1%2.4 $4.31 Get the Latest News and Ratings for EGRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/31/2024423,800 shares $2.18 million -12.5%3.7%2.9 $5.14 8/15/2024484,200 shares $1.93 million +14.1%4.2%3.1 $3.98 7/31/2024424,400 shares $2.05 million -44.9%3.7%2.5 $4.82 7/15/2024770,600 shares $4.60 million -16.8%6.7%4.5 $5.97 6/30/2024925,900 shares $5.19 million -6.9%8.1%5.2 $5.60 6/15/2024994,400 shares $3.83 million -7.9%8.7%6.7 $3.85 5/31/20241,080,000 shares $3.75 million -5.3%9.5%7.1 $3.47 5/15/20241,140,000 shares $5.26 million -5.0%10.0%7.8 $4.61 4/30/20241,200,000 shares $4.91 million +1.7%10.5%7.7 $4.09 4/15/20241,180,000 shares $6.14 million -2.5%10.3%5.9 $5.20 3/31/20241,210,000 shares $6.34 million +4.3%10.6%5.3 $5.24 3/15/20241,160,000 shares $7.02 million +4.5%10.2%5 $6.05 2/29/20241,110,000 shares $6.50 million +4.7%9.7%4.3 $5.86 2/15/20241,060,000 shares $6.20 million +33.2%9.3%3.6 $5.85 1/31/2024796,100 shares $4.67 million +10.1%7.0%2.8 $5.86 1/15/2024723,100 shares $3.28 million +3.7%6.4%2.9 $4.53 12/31/2023697,400 shares $3.65 million +3.9%6.2%3.4 $5.23 12/15/2023671,300 shares $3.11 million +13.7%5.9%3.6 $4.63 11/30/2023590,400 shares $3.45 million -0.7%5.2%3.9 $5.85 11/15/2023594,600 shares $5.25 million -3.7%5.2%5.2 $8.83 10/31/2023617,600 shares $8.48 million +2.4%5.5%5.8 $13.73 10/15/2023602,900 shares $8.10 million +12.5%5.3%4.9 $13.43 9/30/2023536,000 shares $8.45 million -23.9%4.7%4.1 $15.77 9/15/2023704,600 shares $11.42 million +9.9%6.2%5.2 $16.21 8/31/2023640,900 shares $10.86 million -6.1%5.7%3.3 $16.95 8/15/2023682,400 shares $11.63 million +4.5%6.0%3.4 $17.04 7/31/2023653,200 shares $13.56 million -4.0%5.7%3.2 $20.76 7/15/2023680,200 shares $12.50 million +14.6%6.0%3.6 $18.37 6/30/2023593,600 shares $11.54 million -26.9%5.2%3.2 $19.44 6/15/2023812,500 shares $15.41 million +18.6%7.1%4.2 $18.96The Real Reason Silver Prices Are Soaring (Ad)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.I'm offering a new 2025 Silver Wealth Guide and it is now available. 5/31/2023685,200 shares $14.22 million -1.3%6.0%4.1 $20.75 5/15/2023694,400 shares $14.60 million -3.0%6.1%4.3 $21.03 4/30/2023715,700 shares $20.10 million -5.1%6.3%4.7 $28.08 4/15/2023754,400 shares $22.41 million -19.7%6.7%4.8 $29.71 3/31/2023939,300 shares $26.65 million -7.9%8.3%5.5 $28.37 3/15/20231,020,000 shares $26.27 million +16.4%9.0%6.3 $25.75 2/28/2023876,100 shares $24.53 million +1.0%7.8%6.1 $28.00 2/15/2023867,400 shares $26.73 million -0.8%7.7%6.3 $30.82 1/31/2023874,400 shares $29.68 million -9.7%7.7%5.8 $33.94 1/15/2023968,700 shares $31.43 million -2.4%8.6%6.2 $32.45 12/30/2022992,100 shares $29.00 million +63.8%8.8%6.4 $29.23 12/15/2022605,700 shares $17.90 million -27.0%5.4%3.6 $29.55 11/30/2022830,100 shares $30.15 million -9.4%7.3%4.9 $36.32 11/15/2022915,900 shares $33.89 million +0.1%8.1%5.3 $37.00 10/31/2022915,200 shares $28.80 million -6.5%8.1%4.9 $31.47 10/15/2022978,700 shares $27.01 million +8.4%8.5%5.6 $27.60 9/30/2022903,200 shares $23.86 million +28.8%7.8%5.4 $26.42 9/15/2022701,400 shares $21.13 million -17.2%6.1%4.3 $30.12 8/31/2022846,900 shares $27.75 million +3.2%7.4%5.7 $32.77 8/15/2022820,900 shares $29.49 million -18.7%7.2%5.6 $35.92 7/31/20221,010,000 shares $40.10 million +1.0%9.2%7.4 $39.70 7/15/20221,000,000 shares $44.83 million -2.9%9.1%7.5 $44.83 6/30/20221,030,000 shares $45.76 million -7.2%9.4%7.6 $44.43 6/15/20221,110,000 shares $48.33 million +17.4%10.2%8 $43.54 5/31/2022945,600 shares $44.16 million +4.3%8.6%6.8 $46.70 5/15/2022906,800 shares $39.90 million +8.2%8.3%6.8 $44.00 4/30/2022838,200 shares $36.99 million +20.1%7.7%6.4 $44.13 4/15/2022697,800 shares $35.20 million -3.1%6.4%5.5 $50.44 3/31/2022719,800 shares $35.62 million +4.4%N/A5.5 $49.49 3/15/2022689,700 shares $34.69 million +14.0%6.3%5.9 $50.30 2/28/2022604,900 shares $28.67 million -10.2%5.4%4.8 $47.39 2/15/2022673,200 shares $32.15 million +1.1%6.0%5.6 $47.76 1/31/2022665,700 shares $30.58 million +12.4%5.9%5.9 $45.94 1/15/2022592,400 shares $27.97 million +2.3%N/A5.6 $47.21 12/31/2021579,300 shares $29.50 million -1.0%5.2%6 $50.92 12/15/2021585,100 shares $30.60 million -5.5%5.2%5.8 $52.30 11/30/2021618,900 shares $29.51 million -3.3%5.5%7.1 $47.68 11/15/2021639,900 shares $32.62 million -7.1%5.7%6.9 $50.98 10/29/2021689,000 shares $36.08 million -1.7%6.0%7 $52.37 10/15/2021701,000 shares $38.12 million -11.3%6.1%7 $54.38 9/30/2021790,700 shares $44.11 million -4.8%6.9%7.6 $55.78 9/15/2021830,500 shares $43.92 million -3.3%7.3%7.2 $52.88 8/31/2021859,200 shares $45.86 million -6.7%7.5%7.4 $53.37 8/13/2021920,800 shares $44.91 million -5.0%8.1%7.7 $48.77 7/30/2021969,000 shares $45.06 million +4.6%8.5%8.5 $46.50 7/15/2021926,100 shares $43.55 million -3.1%8.1%8.1 $47.02 6/30/2021955,800 shares $40.91 million -7.2%8.4%8.1 $42.80 6/15/20211,030,000 shares $42.73 million -2.8%9.0%9.3 $41.49 5/28/20211,060,000 shares $42.00 million -1.9%9.3%10.1 $39.62 5/14/20211,080,000 shares $43.92 million +2.9%9.4%9.8 $40.67The Real Reason Silver Prices Are Soaring (Ad)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.I'm offering a new 2025 Silver Wealth Guide and it is now available. 4/30/20211,050,000 shares $42.98 million -7.9%9.2%9.1 $40.93 4/15/20211,140,000 shares $49.44 million -16.8%N/A0 $43.37 3/31/20211,370,000 shares $56.25 million -2.1%12.2%11.2 $41.06 3/15/20211,400,000 shares $62.97 million No Change12.4%11 $44.98 2/26/20211,400,000 shares $64.09 million +7.7%12.4%10.8 $45.78 2/12/20211,300,000 shares $62.41 million -7.1%11.6%10.7 $48.01 1/29/20211,400,000 shares $65.63 million -2.1%12.4%11.7 $46.88 1/15/20211,430,000 shares $72.54 million -4.0%12.7%11.4 $50.73 12/31/20201,490,000 shares $69.29 million No Change13.2%11.5 $46.50 12/15/20201,490,000 shares $68.81 million -0.7%13.2%10.6 $46.18 11/30/20201,500,000 shares $70.97 million -3.9%13.3%10.2 $47.31 11/15/20201,560,000 shares $76.30 million -4.9%13.8%9.6 $48.91 10/30/20201,640,000 shares $75.74 million -12.3%14.5%9.8 $46.18 10/15/20201,870,000 shares $85.03 million -18.0%15.9%10.6 $45.47 9/30/20202,280,000 shares $96.85 million +27.4%19.4%13 $42.48 9/15/20201,790,000 shares $69.24 million -10.5%15.1%10 $38.68 8/31/20202,000,000 shares $79.36 million +1.5%16.9%11.3 $39.68 8/14/20201,970,000 shares $84.65 million -5.3%16.4%11.6 $42.97 7/31/20202,080,000 shares $96.49 million +0.5%15.9%11.9 $46.39 7/15/20202,070,000 shares $100.46 million +3.5%15.8%12.8 $48.53 6/30/20202,000,000 shares $95.96 million +8.7%15.3%12 $47.98 6/15/20201,840,000 shares $81.68 million +1.1%14.0%11.2 $44.39 EGRX Short Interest - Frequently Asked Questions What is Eagle Pharmaceuticals' current short interest? Short interest is the volume of Eagle Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 54,400 shares of EGRX short. Learn More on Eagle Pharmaceuticals' current short interest. What is a good short interest ratio for Eagle Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EGRX shares currently have a short interest ratio of 25.0. Learn More on Eagle Pharmaceuticals's short interest ratio. Is Eagle Pharmaceuticals' short interest increasing or decreasing? Eagle Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totaling 54,400 shares, a decrease of 14.7% from the previous total of 63,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Eagle Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Eagle Pharmaceuticals: Cassava Sciences, Inc. (22.91%), Coya Therapeutics, Inc. (2.05%), Kyverna Therapeutics, Inc. (13.20%), C4 Therapeutics, Inc. (9.85%), Genelux Co. (6.96%), OptiNose, Inc. (1.68%), OncoCyte Co. (1.44%), MacroGenics, Inc. (10.51%), Caribou Biosciences, Inc. (11.72%), Lexeo Therapeutics, Inc. (12.44%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks. What does it mean to sell short Eagle Pharmaceuticals stock? Short selling EGRX is an investing strategy that aims to generate trading profit from Eagle Pharmaceuticals as its price is falling. EGRX shares are trading up $0.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Eagle Pharmaceuticals? A short squeeze for Eagle Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of EGRX, which in turn drives the price of the stock up even further. How often is Eagle Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EGRX, twice per month. The most recent reporting period available is May, 15 2025. More Short Interest Resources from MarketBeat Related Companies SAVA Short Squeeze VXRT Short Squeeze CRDL Short Squeeze KRRO Short Squeeze ADAG Short Squeeze ORMP Short Squeeze OPTN Short Squeeze HLVX Short Squeeze CCCC Short Squeeze ANIX Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EGRX) was last updated on 6/5/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe Real Reason Silver Prices Are SoaringElon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind ...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.